AXSM

Axsome Therapeutics, Inc.

Fundamental data last updated:September 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

 


Analyze AXSM on TradingView

VALUATION

P/E

-63.43

Market Cap ($M USD)

$12.00B

Forward P/E

7.41

PEG

0.01

PRICE TO SALES

16.95

PRICE TO BOOK

218.80

EV / EBITDA

-68.99

5-Year Average P/E

Free Cash Flow Yield

-0.59%

DCF Value

$-483.27

Graham Number

N/A

Price to FCF

-169.09

EV to FCF

-167.85

Earnings Yield

-1.58%

FCF Yield

-0.59%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.68

Next Year EPS Growth Estimate

$31.49

Next Year Revenue Growth Estimate

$3.76B

Return on Equity (ROE)

-260.01%

FREE CASH FLOW

Operating Margin

-24.80%

Debt-to-Equity

2.73

Piotroski F-Score

4

Altman Z-Score

8.74

Return on Invested Capital (ROIC)

-64.00%

Current Ratio

1.39

Quick Ratio

1.32

Net Debt to EBITDA

0.51

Interest Coverage

-33.07

Gross Profit margin

92.60%

FCF PER SHARE

$-1.39

REVENUE PER SHARE

$13.83

Analyze AXSM on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Axsome Therapeutics, Inc. significantly. With a DCF value deeply negative and a Graham Number unavailable, the stock’s current valuation appears speculative. Despite a promising Forward P/E of 6.90, the negative Earnings Yield and ROIC of -64% raise red flags about profitability. However, the Altman Z-score of 7.94 suggests financial stability, indicating the company is not at immediate risk of distress. The market cap and consensus target price reflect optimism, but the fundamentals tell a more complex story.

AI Exposure / Tech Reliance

In the biotechnology sector, Axsome is well-positioned to leverage AI for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with technological advancements, potentially enhancing R&D efficiency. However, execution will be key in translating tech potential into tangible results.

The Bull Case

For GARP investors, Axsome offers a compelling narrative of future growth. The astronomical sales growth projection and a Forward PEG of 0.007 suggest significant undervaluation relative to growth potential. While the Piotroski F-Score of 4 is moderate, the company's ability to innovate could drive future profitability. The gross profit margin of 92.6% indicates strong pricing power, crucial for sustaining competitive advantage.

The Bear Case

Despite its growth prospects, Axsome faces structural risks. The Price/Book ratio of 203.89 and Price/Sales of 15.79 indicate overvaluation, especially with negative cash flow metrics like FCF Yield and Price to FCF. The stock's proximity to its 52-week high suggests technical overextension. Additionally, the negative operating margin and high Debt/Equity ratio of 2.73 highlight financial vulnerabilities that could hinder long-term stability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$255.81

Institutional Ownership %

1-Year Beta

0.59

Insider Buying % (6 Mo)

Distance to 52-Week High

2.26%

Distance to 52-Week Low

58.81%

EARNINGS SURPRISE %

-48.24%

50-DAY SMA

$194.52

200-DAY SMA

$158.65

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.